Skip to content

Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies

The Impact of Ras/MAPK Pathway Hyperactivation on Bioenergetic Metabolism and Its Effect on Growth Profile and Bone Metabolism

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06331117
Acronym
3776
Enrollment
120
Registered
2024-03-26
Start date
2021-04-22
Completion date
2026-04-22
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardio-Facio-Cutaneous Syndrome, Costello Syndrome, Noonan Syndrome, RASopathy

Brief summary

Costello syndrome (CS) and cardio-facio cutaneous syndrome (CFCS) belongs to RASopathies, a group of multisystemic disorders caused by unregulated signalling through the RAS/MAPK pathway, an intracellular signalling pathway regulating multiple processes such as cellular proliferation, differentiation, survival, apoptosis and also contributing to oncogenesis. They share a recognizable facial appearance, aged appearance, growth delay, muscle-skeletal anomalies, heart defects, neuropsychological features, skin and ocular abnormalities, and cancer predisposition. Even though life expectancy of individuals with CS and CFCS has increased in the last years due to the improvement of patients' care and a more effective prevention of comorbidities, some of the most challenging aspects impacting on everyday living such as growth failure, accelerate senescence and skeletal-muscle defects, still need to be fully understood. This statement underlies the need to improve clinical research protocols with more innovative techniques (multi-omics profiling) in order to better understand the effect of RAS/MAPK pathway hyperactivations on different systems and to define possible personalized treatments.

Detailed description

Multiomics profiling of the RASopathies

Interventions

DIAGNOSTIC_TESTDiagnostic test

Multiomics profiling

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Clinical and molecularly confirmed diagnosis of a RASopathy

Exclusion criteria

* Only clinical diagnosis of a RASoapthy

Design outcomes

Primary

MeasureTime frameDescription
Metabolomic profile of the RASopathies3 yearsTo perform metabolomic profile in all enrolled RASopahty patients

Countries

Italy

Contacts

Primary ContactChiara Leoni, MD, PhD
chiara.leoni@policlinicogemelli.it0039063381344

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026